Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.56
HSKA's Cash to Debt is ranked higher than
69% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. HSKA: 2.56 )
HSKA' s 10-Year Cash to Debt Range
Min: 0.27   Max: No Debt
Current: 2.56

Equity to Asset 0.53
HSKA's Equity to Asset is ranked higher than
66% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. HSKA: 0.53 )
HSKA' s 10-Year Equity to Asset Range
Min: 0.02   Max: 0.78
Current: 0.53

0.02
0.78
F-Score: 7
Z-Score: 0.20
M-Score: -1.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 4.39
HSKA's Operating margin (%) is ranked higher than
76% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. HSKA: 4.39 )
HSKA' s 10-Year Operating margin (%) Range
Min: -125.26   Max: 6.71
Current: 4.39

-125.26
6.71
Net-margin (%) 3.32
HSKA's Net-margin (%) is ranked higher than
78% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. HSKA: 3.32 )
HSKA' s 10-Year Net-margin (%) Range
Min: -132.76   Max: 42.28
Current: 3.32

-132.76
42.28
ROE (%) 6.08
HSKA's ROE (%) is ranked higher than
78% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. HSKA: 6.08 )
HSKA' s 10-Year ROE (%) Range
Min: -104.28   Max: 140.27
Current: 6.08

-104.28
140.27
ROA (%) 3.12
HSKA's ROA (%) is ranked higher than
80% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. HSKA: 3.12 )
HSKA' s 10-Year ROA (%) Range
Min: -69.96   Max: 61.02
Current: 3.12

-69.96
61.02
ROC (Joel Greenblatt) (%) 16.24
HSKA's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. HSKA: 16.24 )
HSKA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -176.87   Max: 22.95
Current: 16.24

-176.87
22.95
Revenue Growth (%) 3.00
HSKA's Revenue Growth (%) is ranked higher than
72% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. HSKA: 3.00 )
HSKA' s 10-Year Revenue Growth (%) Range
Min: -16.9   Max: 10.4
Current: 3

-16.9
10.4
EBITDA Growth (%) -24.60
HSKA's EBITDA Growth (%) is ranked higher than
60% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. HSKA: -24.60 )
HSKA' s 10-Year EBITDA Growth (%) Range
Min: -63.9   Max: 27.7
Current: -24.6

-63.9
27.7
» HSKA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

HSKA Guru Trades in Q4 2013

Mario Gabelli 61,935 sh (+2.48%)
Jim Simons 70,380 sh (-13.94%)
» More
Q1 2014

HSKA Guru Trades in Q1 2014

Mario Gabelli 59,935 sh (-3.23%)
Jim Simons 55,880 sh (-20.6%)
» More
Q2 2014

HSKA Guru Trades in Q2 2014

Jim Simons 65,980 sh (+18.07%)
Mario Gabelli 58,000 sh (-3.23%)
» More
Q3 2014

HSKA Guru Trades in Q3 2014

Jim Simons 106,880 sh (+61.99%)
Mario Gabelli 57,500 sh (-0.86%)
» More
» Details

Insider Trades

Latest Guru Trades with HSKA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2012-12-31 Add 29.08%$7.96 - $9.54 $ 16.8393%62135
Mario Gabelli 2012-09-30 Add 50.73%$7.78 - $11.3 $ 16.8379%48135
Mario Gabelli 2012-06-30 Add 56.54%$10.9 - $12.85 $ 16.8342%31935
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 34.90
HSKA's P/E(ttm) is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. HSKA: 34.90 )
HSKA' s 10-Year P/E(ttm) Range
Min: 0.5   Max: 549.09
Current: 34.9

0.5
549.09
P/B 2.10
HSKA's P/B is ranked higher than
90% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. HSKA: 2.10 )
HSKA' s 10-Year P/B Range
Min: 0.22   Max: 75.45
Current: 2.1

0.22
75.45
P/S 1.20
HSKA's P/S is ranked higher than
92% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. HSKA: 1.20 )
HSKA' s 10-Year P/S Range
Min: 0.12   Max: 2.24
Current: 1.2

0.12
2.24
PFCF 93.50
HSKA's PFCF is ranked higher than
80% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. HSKA: 93.50 )
HSKA' s 10-Year PFCF Range
Min: 2.45   Max: 463
Current: 93.5

2.45
463
EV-to-EBIT 30.29
HSKA's EV-to-EBIT is ranked higher than
81% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. HSKA: 30.29 )
HSKA' s 10-Year EV-to-EBIT Range
Min: -122.2   Max: 164.2
Current: 30.29

-122.2
164.2
Shiller P/E 135.00
HSKA's Shiller P/E is ranked higher than
85% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. HSKA: 135.00 )
HSKA' s 10-Year Shiller P/E Range
Min: 1.88   Max: 140.08
Current: 135

1.88
140.08
Current Ratio 2.04
HSKA's Current Ratio is ranked higher than
64% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. HSKA: 2.04 )
HSKA' s 10-Year Current Ratio Range
Min: 1.03   Max: 5.19
Current: 2.04

1.03
5.19
Quick Ratio 1.33
HSKA's Quick Ratio is ranked higher than
58% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. HSKA: 1.33 )
HSKA' s 10-Year Quick Ratio Range
Min: 0.56   Max: 4.4
Current: 1.33

0.56
4.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.90
HSKA's Dividend Yield is ranked lower than
65% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.31 vs. HSKA: 0.90 )
HSKA' s 10-Year Dividend Yield Range
Min: 0.79   Max: 3.73
Current: 0.9

0.79
3.73
Yield on cost (5-Year) 0.90
HSKA's Yield on cost (5-Year) is ranked lower than
68% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. HSKA: 0.90 )
HSKA' s 10-Year Yield on cost (5-Year) Range
Min: 0.79   Max: 3.73
Current: 0.9

0.79
3.73
Share Buyback Rate -3.10
HSKA's Share Buyback Rate is ranked higher than
77% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.60 vs. HSKA: -3.10 )
HSKA' s 10-Year Share Buyback Rate Range
Min: 1.8   Max: -29.6
Current: -3.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.53
HSKA's Price/Tangible Book is ranked higher than
85% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. HSKA: 3.53 )
HSKA' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 261.43
Current: 3.53

0.3
261.43
Price/DCF (Projected) 2.09
HSKA's Price/DCF (Projected) is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. HSKA: 2.09 )
HSKA' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 20.11
Current: 2.09

0.57
20.11
Price/Median PS Value 1.67
HSKA's Price/Median PS Value is ranked higher than
66% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. HSKA: 1.67 )
HSKA' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 18.7
Current: 1.67

0.23
18.7
Price/Graham Number 2.40
HSKA's Price/Graham Number is ranked higher than
91% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. HSKA: 2.40 )
HSKA' s 10-Year Price/Graham Number Range
Min: 0.19   Max: 26.4
Current: 2.4

0.19
26.4
Earnings Yield (Greenblatt) 3.30
HSKA's Earnings Yield (Greenblatt) is ranked higher than
80% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. HSKA: 3.30 )
HSKA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 20.7
Current: 3.3

0.6
20.7
Forward Rate of Return (Yacktman) 0.45
HSKA's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.35 vs. HSKA: 0.45 )
HSKA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -90.7   Max: 7.5
Current: 0.45

-90.7
7.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Heska Corp was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. The Company develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it provides high value products. The Company's business is comprised of two reportable segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment includes mainly for canine and feline use, blood testing instruments and supplies as well as single use products and services such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. These products are sold directly to veterinarians by the Company as well as through distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals. All OVP products are sold by third parties under third party labels. It provides line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases and Electrolytes; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is a blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The Element POC Blood Gas & Electrolyte Analyzer is a handheld, wireless analyzer which delivers rapid blood gas, electrolyte, metabolite, and basic blood chemistry testing. EPOC features test cards with room temperature storage which can provide results with less than 100 µL of sample as well as WiFi and Bluetooth connectivity. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories in Loveland, Colorado and Fribourg, Switzerland which both provide blood testing using its ALLERCEPT Definitive Allergen Panels. Its competitors include: IDEXX Laboratories, Inc., Abaxis, Inc. and Synbiotics Corporation.
» More Articles for HSKA

Headlines

Articles On GuruFocus.com
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 5,000 Shares Jun 01 2010 
Heska Corp. (HSKA) CEO Robert B Grieve buys 6,500 Shares May 21 2010 
Weekly CFO Buys Highlight: ZixIt, Global Defense Technology and Systems, FelCor Lodging Trust, Heska Mar 07 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 1,000 Shares Mar 01 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 
Heska Corp. (HSKA) President and COO Michael J Mcginley buys 12,290 Shares Feb 26 2010 

More From Our Partners
One Stock Chart Trick You Should All Know - Investment Ideas Dec 16 2014 - ZACKS

More From Other Websites
Coverage initiated on Heska Corp by Gabelli & Co Dec 12 2014
Heska to Attend Benchmark Micro Cap Discovery Conference Nov 25 2014
HESKA CORP Financials Nov 18 2014
10-Q for Heska Corp. Nov 12 2014
HESKA CORP Files SEC form 10-Q, Quarterly Report Nov 10 2014
Heska Announces Investor Day in New York City Nov 04 2014
Heska Announces Investor Day in New York City Nov 04 2014
Can the Rally in Heska (HSKA) Shares Continue? Oct 30 2014
Heska Reports 24% Revenue Growth, $0.08 Per Share for the Third Quarter of 2014 Oct 29 2014
HESKA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 29 2014
Heska Signs Distribution Agreement with Henry Schein Animal Health Oct 29 2014
Heska Reports 24% Revenue Growth, $0.08 Per Share for the Third Quarter of 2014 Oct 29 2014
Heska Signs Distribution Agreement with Henry Schein Animal Health Oct 29 2014
Q3 2014 Heska Corp Earnings Release - Before Market Open Oct 29 2014
Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast Oct 28 2014
Heska Announces Q3 2014 Earnings Conference Call Oct 24 2014
Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast Oct 24 2014
Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% Sep 29 2014
Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% Sep 26 2014
Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher Sep 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK